Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Name: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Published: 2012
License: Public Domain

Janssen Research & Development, LLC · 2012

ClinicalTrials.gov · Datasets · License: Public Domain · 2012

Open Source ↗

mantle cell lymphoma, relapsed mantle cell lymphoma, refractory mantle cell lymphoma, ibrutinib, bruton's tyrosine kinase inhibitor, temsirolimus, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Related documents